Woodline Partners’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-859,105
| Closed | -$34.1M | – | 1050 |
|
|
2026
Q1 | $34.1M | Buy |
859,105
+280,854
| +49% | +$7.18M | 0.13% | 213 |
|
|
2025
Q4 | $14.5M | Buy |
578,251
+470,580
| +437% | +$11.9M | 0.06% | 375 |
|
|
2025
Q3 | $2.61M | Sell |
107,671
-292,607
| -73% | -$5.2M | 0.01% | 691 |
|
|
2025
Q2 | $5.26M | Hold |
400,278
| – | – | 0.03% | 547 |
|
|
2025
Q1 | $5.76M | Sell |
400,278
-145,367
| -27% | -$2.38M | 0.04% | 469 |
|
|
2024
Q4 | $9.14M | Buy |
545,645
+29,266
| +6% | +$485K | 0.06% | 364 |
|
|
2024
Q3 | $8.26M | Buy |
516,379
+392,918
| +318% | +$4.81M | 0.07% | 330 |
|
|
2024
Q2 | $1.11M | Buy |
+123,461
| New | +$1.17M | 0.01% | 453 |
|
|
2024
Q1 | – | Sell |
-140,856
| Closed | -$1.12M | – | 554 |
|
|
2023
Q4 | $1.12M | Sell |
140,856
-69,348
| -33% | -$465K | 0.01% | 400 |
|
|
2023
Q3 | $1.36M | Sell |
210,204
-477,559
| -69% | -$3.27M | 0.02% | 425 |
|
|
2023
Q2 | $4.26M | Sell |
687,763
-48,230
| -7% | -$229K | 0.05% | 315 |
|
|
2023
Q1 | $2.83M | Buy |
735,993
+516,573
| +235% | +$1.89M | 0.04% | 377 |
|
|
2022
Q4 | $680K | Buy |
219,420
+40,852
| +23% | +$151K | 0.01% | 574 |
|
|
2022
Q3 | $718K | Sell |
178,568
-1,136,084
| -86% | -$5.2M | 0.01% | 561 |
|
|
2022
Q2 | $6.4M | Buy |
1,314,652
+432,019
| +49% | +$2.76M | 0.1% | 223 |
|
|
2022
Q1 | $7.92M | Buy |
882,633
+81,497
| +10% | +$743K | 0.13% | 195 |
|
|
2021
Q4 | $9.02M | Sell |
801,136
-81,677
| -9% | -$1.1M | 0.13% | 210 |
|
|
2021
Q3 | $14.7M | Buy |
882,813
+60,295
| +7% | +$1.25M | 0.24% | 115 |
|
|
2021
Q2 | $18.3M | Buy |
+822,518
| New | +$19.3M | 0.34% | 77 |
|
Woodline Partners's CNTA Position: Q2 2026 in Review
Woodline Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 859,105 shares — an estimated $34.1M sold.
Woodline Partners first reported a position in CNTA in Q2 2021 and held it in 19 quarters. The position peaked at $34.1M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Woodline Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Woodline Partners sold 859,105 Centessa Pharmaceuticals shares in Q2 2026, an estimated $34.1M.
- Woodline Partners first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- Woodline Partners's Centessa Pharmaceuticals position peaked at $34.1M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.